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Discussing potential recurrence after lung cancer surgery: 
uncertainties and challenges 
Abstract 
Patients with lung cancer who undergo surgery may potentially be cured. The 
resulting pathological staging gives an indication of 5-year survival and whether 
further treatment is recommended. To date, there is little research evidence 
regarding the way potential recurrence is communicated to patients by staff. 
This qualitative research used case studies to explore how information 
disclosure about possible recurrence was managed following lung cancer surgery 
and aimed to identify practice implications for clinical teams.  Twelve patients 
were recruited and first post-operative surgical and subsequent oncology or 
follow-up consultations were recorded and transcribed. The perspective of the 
professionals involved in these clinics was ascertained through 30 in-depth 
interviews. Key themes in the data were identified using Framework Analysis. 
Recurrence risk was communicated to patients in a number of ways and levels of 
clarity and openness. Information provided by participants about early warning 
signs of recurrence varied. Findings indicate information provided was linked to 
the patient’s prognosis and individual professionals’ underlying communication 
approach. This study provides a unique insight into the views of lung cancer 
specialists regarding information disclosure and reveals the challenging nature 
and complexity of discussing recurrence following lung cancer surgery.  
Keywords: 
 
Lung cancer; surgery; recurrence risk; information; communication; case study 
research, UK  
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Introduction 
For patients who have a lung cancer that is amenable to surgery, having an 
operation is often seen as offering hope of a cure (Powell et al., 2015). Recent 
international survival data indicates that five-year survival for patients 
diagnosed with stage 1A lung cancer is 83%, while those diagnosed with a stage 
3A cancer is 36% (Goldstraw et al., 2016). Dealing with the possibility of cancer 
recurrence can be a day-to-day reality following treatment.  How this reality is 
presented and discussed with patients and how they are supported following 
surgery is therefore of clinical importance.  
 
Patients are offered surgery based on clinical stage of the lung cancer as well as 
overall fitness for surgery (National Collaborating Centre for Cancer, 2011). 
Patients who have surgery will have a definitive pathological staging as a result 
of analysis of the whole tumour and associated lymph node samples. Depending 
on this staging, patients may or may not be offered adjuvant treatment (Lim et 
al., 2010). Meta-analyses of trials suggest that adjuvant chemotherapy can add 
around 4% improvement in absolute survival at 5 years (NSCLC Meta-analysis 
Collaborative Group, 2010). Following surgery and any adjuvant treatment, 
patients undergo a period of regular surveillance, typically over a period of five 
years. There is lack of consensus on the most effective strategy and frequency for 
following up patients after surgery (Schmidt-Hansen, Baldwin, & Hasler, 2012).    
 
Patients generally consider the consultation following surgery to be very 
significant, representing a transition from one phase of their illness to another 
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(Thorne & Stajduhar, 2012).  Such transitions create challenges, particularly 
regarding communicating potential risk of recurrence. Patients’ preferences for 
information may vary; while some patients may find discussion of potential 
recurrence very challenging, or even irrelevant, some patients may also see it as 
an essential element of their information needs (Thorne & Stajduhar, 2012).   
Patients may use this information for various reasons, including decision-making 
about further treatment, managing inherent uncertainty, or gaining a sense of 
control over their illness (Thorne, Hislop, Kuo, & Armstrong, 2006). Current 
national and international guidelines on communication with patients suggest 
that patients should be empowered to take a shared role in decision-making 
about their care (National Cancer Taskforce, 2015). However, British Thoracic 
Society guidelines urge caution when discussing definitive lung cancer prognosis 
and stage, due to the complexities and the potential for questions patients may 
not be emotionally equipped to deal with (British Thoracic Society, 2013). Such 
divergences in guidelines can create a dilemma for practitioners. 
 
Prognostic communication can have an impact on patients’ sense of hope, both 
positively and negatively (Thorne, Oglov, Armstrong, & Hislop, 2007).  Two 
published reviews have explored prognostic communication in the wider cancer 
population (Hagerty, Butow, Ellis, Dimitry, & Tattersall, 2005; Johnson, Tod, 
Brummell, & Collins, 2015). Much of the evidence on prognostic communication 
has focused on the breast cancer population. Clinicians may convey a sense of 
optimism for cure following surgery, despite the inherent risk of recurrence in 
the future (Step & Ray, 2011). Furthermore, studies of post-surgical clinics 
suggested that goals for communication for both patients and clinicians were to 
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facilitate hope (Mendick, Young, Holcombe, & Salmon, 2011). While clinicians 
gave some biomedical information in all consultations, hope was conveyed by 
positive evaluations of prognosis and further treatment. Where prognosis was 
poorer, clinicians focused more on factual biomedical information and positive 
evaluation was limited to factors such as surgical recovery (Mendick, Young, 
Holcombe, & Salmon, 2013). In this way, hope was maintained by focusing on 
things other than long-term outcome.  
 
Prognostic forecasting is inherently imprecise and uncertain. Uncertainty also 
arises from the unpredictability of events for an individual patient. Individuals 
are prone to the “irreducible randomness and indeterminacy of natural events” 
(Han, Klein, & Arora, 2011, p832). Managing and communicating uncertainty and 
risk can be challenging particularly in high stakes situations such as discussing 
recurrence risk after lung cancer surgery.  Patients and professionals may have 
differing beliefs and understanding of these aspects of uncertainty. This can lead 
to very different attitudes when seeking or delivering information and the values 
attached to information based on statistics. Moreover, people can struggle to 
interpret statistical and population based information in relation to 
individualised risk (Han et al., 2009; Powell et al., 2015). Patients’ subjective and 
emotional response to such information forms an intrinsic, and often dominant, 
part of patients’ understanding of their situation (Zikmund-Fisher, Fagerlin, & 
Ubel, 2010).  
 
Reyna, (2012) describes two different mental representations of information 
presented to patients: ‘verbatim’ and ‘gist’ memory. Gist memory focuses only on 
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‘fuzzy’ detail and incorporates the subjective, emotional and psychological 
elements to create meaning. This works in parallel with the exact recall of 
verbatim memory. People have a preference for encoding meaning at the gist 
level, but seek further detail if and when they consider it necessary (Reyna, 
Nelson, Han, & Pignone, 2015). In the context of recurrence risk communication, 
it is likely that most patients will take away only a stripped-down impression of 
the information they are given. However, when provided with numerical 
information, this can become particularly poignant and memorable for patients 
with cancer (Thorne et al., 2006). Hence statistical information presented during 
consultations may be recalled, but the context lost, leading to its implications 
being misconstrued. 
 
Risk constructs can be presented in many different formats and range from 
implicit information to specific probabilities.  Different formats will be better 
suited to conveying risk in different situations (Zikmund-Fisher, 2013). The key 
distinctions lie between presenting the possibility that an event can happen, thus 
avoiding any precision, and giving probability estimations, detailing risk with 
more precision by using numbers. Different levels of detail can be conveyed by 
placing these risks in context; by comparing with other situations and by 
presenting risk in relation to particular circumstances or choices. Use of these 
different forms of risk communication tailors risk information to the level of 
specificity perceived as appropriate to the situation. 
 
There is a paucity of research that examines the specific issues around 
communication and disclosure of possible recurrence for patients with lung 
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cancer following surgery. This qualitative study aimed to partly address the 
evidence gap.  It explored how information regarding possible recurrence was 
presented to patients and to gain insight into the way in which professionals 
manage this process in lung cancer clinical practice.  The specific study 
objectives were to: 
 Identify what information is given to patients regarding the long-term 
risk of lung cancer recurrence and/or survival after surgery 
 Identify who gives this information. 
 Explore the perceptions of different professionals regarding their role 
when discussing long-term risk of recurrence or survival after lung 
cancer surgery, including how they discriminate what information to 
disclose. 
Methods  
Due to the exploratory nature of this research it was important to gain an in-
depth understanding of the way in which the subject of potential recurrence was 
managed, both by clinical teams and by patients and to examine underpinning 
attitudes and decisions. Therefore a qualitative research approach was taken 
(Ritchie, Lewis, McNaughton Nichols, & Ormston, 2014). Case study methodology 
provided a mechanism to explore communication of recurrence over time and in 
clinic settings (Yin, 2014). The post-surgical clinic is usually where the pathology 
results are first presented to the patient and was taken as the starting point of 
the study. Formal research ethics committee approval was gained (reference 
15/LO/1183). 
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Sample identification and recruitment method 
Patients in the study were referred to two UK specialist thoracic surgery units 
from three, secondary care local lung cancer multidisciplinary teams (MDT). The 
study was conducted at the surgical units and at the local lung cancer hospitals. 
Figure 1 outlines the sample recruitment and data collection points in the study. 
Lung cancer nurse specialists (LCNS) based at the surgical centres, not otherwise 
involved in the study, identified potential patients while admitted for their 
surgery using predetermined inclusion/exclusion criteria (see box 1). Purposive 
sampling was used to identify a wide range of lung cancer patients in terms of 
age, stage and previous health experience, all undergoing potentially curative 
surgery, in line with the qualitative methods used. Written consent was obtained 
from patients and staff members involved in the study. 
Sample size 
Twelve patients were recruited and formed the cases of the study. A total of 20 
health professionals were involved in the observed consultations with these 
patients and were recruited to the study. They consisted of eight surgeons (four 
consultants, four registrars; three female, five male), four oncologists (all 
consultants; two male, two female), two chest physicians (both consultants, one 
male one female) and six LCNS (all female). If professionals saw more than one 
study patient they were interviewed for each occasion. In total, 30 interviews 
were conducted across the 20 health professional participants (see table 1 for 
details of the patient cases and the clinical staff involved).    
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Ideally recruitment should continue until data saturation has been achieved 
across all themes. In reality this was a challenge due to the limited number of 
oncologists and professionals undertaking follow-up within each MDT pathway. 
However, the sample did contain a wide range of experience from both the 
patient and professional perspective (Baker & Edwards, 2012; Hennink, Kaiser, 
& Marconi, 2017).  
 
Data collection 
Observation of the first post-operative surgical and subsequent oncology or 
follow-up clinics were conducted. All patients attended a post-operative surgical 
clinic. Depending on the practice of the MDT, patients were seen either at the 
thoracic unit, or at the local lung cancer hospital. Six patients were referred for 
consideration of adjuvant therapy and were seen locally in an oncology 
assessment clinic. Six other patients were referred for follow-up care with their 
local lung cancer team and the first appointment was observed. The researcher 
(MJ) attended clinics as a participant observer with the patient. All consultations 
were audio recorded, transcribed and written notes taken.  Surgical clinics lasted 
an average of 17 minutes (range 7 – 31 minutes). Oncology clinics lasted an 
average of 39 minutes (range 19 – 48 minutes) and follow-up clinics an average 
of 24 minutes (range 7 – 43 minutes). 
 
One-to-one interviews were completed with the surgeon, oncologist, chest 
physician and or LCNS who saw the patients in the clinics to ascertain their 
perspective and understand rationale for particular information giving. 
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Interviews took place as soon as possible after the clinic by one researcher (MJ), 
following a semi-structured topic guide (Tod, 2013). (Interview topic guide: see 
box 2). Interviews lasted an average of 30 minutes (range 10 – 60 minutes).  
Data analysis  
Clinic consultations and interviews were transcribed verbatim. Observational 
comments and field notes were added to the transcripts for inclusion in the 
analysis. Framework Analysis was used (Ritchie et al., 2014). This involved a 
process of data familiarisation and development of an initial descriptive coding 
schema. Other members of the research team (AT, KC & SB) reviewed a number 
of these transcripts for coding consistency and validity of the themes. An initial 
thematic framework was developed and an iterative process of applying the 
thematic framework, modifying and re-applying, facilitated its development to 
achieve the best possible fit with the data. The computer assisted qualitative data 
analysis tool, NVivo 10 (QSR International Pty Ltd 2014), was used to index and 
sort the data by applying the final thematic framework (Silver & Lewins, 2014). 
Matrices were constructed, allowing data to be visualised and analysed across 
and within cases (Ritchie et al., 2014). Abstraction and interpretation of the data 
was facilitated by further analysis of groups of themes to identify linkages and 
patterns in the data. 
Results  
Findings from clinic observations and professional interviews were combined 
and presented below. Three key themes were identified in this data. The first 
theme The range of the risk of recurrence information was divided into three 
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sub-themes; Probability versus possibility, Effect of prognosis on risk of 
recurrence information and Uncertainty challenges. The second theme 
explored Discussing early warning signs of recurrence. The final theme 
explored professionals Getting the balance right for patients.  Excerpts from 
the original data are presented throughout to illustrate the findings. 
 
Theme 1: The range of risk of recurrence information 
Information presented regarding risk of lung cancer recurrence was given in a 
range of ways. Recurrence was discussed in relation to surgical findings, the 
potential role of adjuvant treatment, follow-up and surveillance and the 
recognition of early signs of recurrence. Recurrence information was identified 
in the clinic transcripts and classified according to risk communication 
typologies closely based on those derived by Zikmund-Fisher (2013). Examples 
taken from the clinic transcriptions for each typology are displayed in table 2. 
The most explicit form of recurrence information was classified for each 
encounter and displayed in table 3. Cases were grouped into patients who were 
perceived by their surgeon to have a relatively “good prognosis” and patients 
with poorer prognosis, labelled “intermediate prognosis”.   
 
Probability vs possibility 
Information was given in a range of ways, from using vague ‘implicit possibility’ 
of recurrence, to giving ‘absolute probability’ of recurrence or 5-year survival 
(See table 2 for examples). One surgeon explained why he felt the survival 
statistics should be given routinely to patients, both as part of the surgical 
 12 
informed consent process, and as part of discussing the post-operative surgical 
outcome. 
“I would try and give the number every time I have it. Because we have that 
information available for each stage of the cancer, each type of the cancer, 
given the fitness. Although we do not have very reliable predictors for the 
morbidity, we do have […] very strong available evidence in terms of five-
year survival for a given stage.” [Surgeon 8 interview about Patient 11] 
 
Other staff avoided giving numbers to patients unless patients 'pushed' for this, 
or even avoided giving this sort of information at all. Professionals gave a range 
of reasons during the interviews. Staff identified the problem of applying 
population statistics to individual patients.  
“[…] although we’ve got good population statistics, really what matters to 
the individual patient is what’s going to happen to them, and obviously she’s 
either going to live or die and unfortunately we really can’t tell.  So unless 
somebody is pushing, I tend not to give a lot of figures about five-year 
survival because we genuinely don’t know which side of that they’re going 
to come down on.” [Oncologist 1 interview about Patient 1] 
Some staff talked about the difficulties patients had interpreting this sort of data, 
leading to an increased risk of misunderstanding and raising anxiety. 
“I think they can get so bombarded by statistics and a lack of clarity about it 
that they can end up coming away from the consultation not sure whether 
they have made the right decision or not.” [LCNS 3 interview about Patient 
5]  
Others highlighted the potential to damage patients’ hope. 
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“So if I tell him now in five years [he] might be dead or [he] might be alive 
50/50. How do you think it’s going to impact his psychology? […] I 
remember him when he went home; he was more depressed and unwell 
looking. Now when he came [to clinic today] he said, ‘I’m feeling good’. And 
that keeps you alive.” [Surgeon 6 interview about Patient 10] 
Findings showed a wide range of strongly held views amongst clinical staff about 
offering assessments of prognosis to patients, which clearly influenced their 
practice. 
 
Effect of prognosis on risk of recurrence information  
Where staff perceived a good prognosis patients were told about their good 
outcome from surgery.  
“[…] for the patients who perhaps come back and their histology is good in 
terms of staging and in terms of complete resection, then I make that very 
clear in the consultation and I’ll often sort of say, you know, the points to 
take away are that it was early lung cancer, that we’ve got it all out, and 
that at this stage we don’t need any further treatment. So I think it’s 
important that, if that’s the case, that people go away feeling […] that it was 
all worthwhile […].” [Surgeon 4 interview about Patient 6] 
 
Consultations differed as to how much this was explicitly flagged as good news, 
but patients were all told further treatment was not required. With the exception 
of Patient 11, who had already been given this information by the surgeon, 
patients went on to ask about cancer recurrence. However, not all patients 
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received answers in terms of probability. Questions were mainly answered with 
‘categorical possibility’, such as “the risk is very low”, or “it is unlikely”. In contrast 
with the surgical clinics, in the follow-up clinics recurrence was frequently not 
discussed, or only implied in discussion about on-going monitoring. 
 
Despite wishing to convey certainty about the future to patients, staff were 
cautious about the concept of cure.  
“[…] people want to hear the cure word or use the cure word and we tread 
very carefully with that generally, or those of us that work in lung cancer 
for long enough.” [LCNS 4 interview about Patient 6] 
Staff talked about there being no guarantee of cure and this concept was used 
during clinics. 
Surgeon 2: It is unlikely, but we cannot say one hundred per cent that you 
won’t have a reoccurrence again. [Surgical clinic transcript Patient 4] 
 
Patients with a less favourable prognosis were seen as more of a communication 
challenge.  
“I think it becomes really difficult when you have anything more than your 
stage 1 cancer. Anything in between stage 4 and stage 1 becomes a difficult 
discussion because now you’re not dealing with good numbers or terrible 
numbers, it’s somewhere in between […].” [Surgeon 5 interview about 
Patient 9] 
For patients with an intermediate prognosis, surgeons presented factual 
biomedical information such tumour size, or lymph node involvement. Where 
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cancer recurrence was specifically mentioned, this was in terms of possibility, or 
implied by talking about referral to an oncologist. Only one patient in this group 
asked any questions about recurrence. Staff presented an ambiguous situation 
and avoided discussion of any negative survival statistics. Staff emphasised hope 
in less factual terms. 
“I'm trying, when I'm explaining to him, to say that the glass is not half 
empty, but half full, you know what I mean? I'm saying to them yes, you are 
getting lung cancer. But. Always but.” [Surgeon 3 interview about Patient 5] 
 
Oncologists used discussion of possible cancer recurrence with all the patients 
referred to them as lead-in and context for introducing potential further 
treatment. However, discussions about recurrence were presented in terms of 
possibility rather than probability. Oncologists sometimes used ‘comparative 
possibility’ of recurrence to explain the rationale for chemotherapy. 
Oncologist 1: […] when it has travelled to the lymph nodes, unfortunately it 
does mean that it is a bit more likely to flare up in the future. Because it has 
proven its ability to travel from one part to another […]. [Patient 8 oncology 
clinic transcript]  
 
Oncologists discussed benefit of adjuvant treatment with the patients referred to 
them in terms of survival advantage or reducing recurrence with adjuvant 
therapy. Several patients were given an ‘incremental probability’, indicating the 
increase in 5-year survival with chemotherapy, based on results of clinical trials. 
Oncologist 1: Because we know sometimes it can come back, people have 
looked at over the years at deciding whether giving some chemotherapy at 
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this sort of stage might help. And the answer is that it does make a bit of 
difference. So if you were to take a group of 100 people and gave all that 
100 people chemo, it would help about six of those people not to run into 
troubles over the next five years. [Patient 2 oncology clinic transcript] 
The oncologist left unspoken the underlying risk of recurrence with which to 
contextualise the benefits. None of the patients asked for this information. One of 
the oncologists commented on this being a common phenomenon.  
“When I say you have a chance of a cure, the chemotherapy increases that 
chance of a cure by 5 in a 100 for every person that I treat, my obvious 
question would be, so what’s my chance anyway? And she didn’t ask that, 
but virtually nobody else does […].” [Oncologist 4 interview about Patient 
12] 
When asked if she would offer this information to patients, she said no, adding: 
“Because they don’t ask. Very much […] the oncology training is towards the 
patient as an individual requesting information, and being given the 
information at the pace they want it, at the time they want it.” 
 
Uncertainty challenges 
Patients with microscopically incomplete resections (denoted as R1) posed 
difficulties for clinicians. Predicting what impact this would have on the long-
term outcome for patients was a challenge due to lack of evidence specific to this 
group.  
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“[…] so if you look at the survival curves you only have T stages, N stages, 
and there’s no survival curve for R. So I wouldn’t know what her five-year 
survival is.” [Surgeon 5 interview about Patient 9] 
Conveying the uncertainty and complexity of this situation to patients also posed 
challenges.  
Oncologist 3: So the surgeon has got rid of what they could see. Under the 
microscope they can see that it goes to the cut point. So microscopically, 
under the microscope, it may have stopped right at the cut point and 
actually they have done a brilliant job and cookie-cuttered it out. Or it could 
have been beyond the other side of the cut point. If it is on the other side of 
the cut point, it may scar and die, or it might persist and grow and then be 
able to come back at that point. [Patient 9 oncology clinic transcript] 
 
Another case that was challenging to provide a prognosis for was patient 6. She 
had been diagnosed with stage 3B cancer, initially received palliative 
chemotherapy, followed by maintenance therapy and was finally referred for 
surgery. The post-surgical pathology showed no active cancer. She asked about 
her risk of the cancer returning in the future, but staff were unable to offer clear 
estimations of the chance of cancer recurrence. 
Patient 6: Is it liable to pop up again? 
Surgeon 4: With anyone with lung cancer we very much work on averages 
and what happens in most people. So even with people who do follow what 
we would expect, things are never straightforward. And even more so in 
your case, we just don't know the answer. [Patient 6 surgical clinic 
transcript] 
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Despite this, the surgeon went on to acknowledge to her that the signs were 
good. Her oncologist was also unable to give a definitive answer during the 
interview.  
“So she's not completely risk-free, but what the percentage is... Because this 
is such an unusual case. I mean, in […] the many years I worked […] treating 
lung cancer, I've never seen this. We just have to watch and see. I can't put a 
figure on it at all I'm afraid.” [Oncologist 2 interview about Patient 6] 
 
Theme 2: Recognising early signs of recurrence 
Information about recognising early warning signs of recurrence was very 
limited in all the clinics. During the surgical clinic, only Surgeon 8 provided any 
information on the signs of potential recurrence and what to do about this if it 
occurred.  For most patients seen in the follow-up clinic there was only either a 
vague mention of new symptoms, or not discussed at all. In one exception the 
patient was given specific information on symptoms to look out for, even though 
recurrence or role of adjuvant adjuvant therapy was not explicitly discussed. 
Chest Physician 1: And we will see you again in three months. If you start 
noticing that you are getting more breathless or that you get a new 
persisting cough, blood in your phlegm, or anything that is concerning you, 
you have got our contact details. [Patient 10 follow-up clinic transcript] 
 
During the oncology clinics some patients were given information about early 
signs of recurrence. The guidance offered tended to emphasise the subtle nature 
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of the symptoms that might indicate a possible recurrence and the importance of 
not assuming all new symptoms were due to cancer.  
Oncologist 3: Listen to that core message of happy, not happy, comfortable, 
not comfortable, rather than the little niggles. Because the little niggles that 
come and go are very rarely anything to do with cancer. So if it comes and 
goes away on its own, isn't cancer. [Patient 9 oncology clinic transcript] 
Where they occurred, these explicit acknowledgements of possible cancer 
recurrence appear aimed at addressing the inherent uncertainty and fear of 
cancer recurrence. 
 
Several professionals were concerned about the timing of discussions with 
patients about awareness of early signs of recurrence. Some were concerned 
about giving patients mixed messages during the surgical clinic by talking about 
good outcomes and discussing potential recurrence at the same time. Even later 
on during follow-up, staff were cautious about 'frightening people' too early on 
after surgery with discussion about possible recurrence.  
“I just don’t know that seeing somebody potentially eight weeks after an 
operation saying you might not be cured and it might come back, I don’t feel 
is the right thing to do […].” [LCNS 2 interview about Patient 3]  
Some professionals spoke about introducing the topic over several clinic visits in 
the context of the rationale behind surveillance. However, none of the 
participants was able to specify when the best time would be. 
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Theme 3: Getting the balance right  
Professionals described giving information that was aimed at supporting hope, 
aiding treatment understanding, or facilitating decision-making. Choices made 
by professionals about what information was disclosed and the depth it was 
given, were complex, often tacit, and tailored to a context. Individual 
professionals differed in their communication ethos and where they situated 
themselves between being an optimist or a realist. While Surgeon 8 was alone in 
seeing his role as giving objective scientific evidence, many other staff spoke 
about the need not to be brutal or “all doom and gloom” and to “be encouraging”. 
Many spoke about tailoring the information to the individual and the difficulties 
in getting the balance right for people.  
 
Several professionals felt that it was essential to provide hope by delivering an 
optimistic message, even if the news was not particularly good.  
“[…] what I’ve learned from my previous consultant is even if the news is not 
that good, you need to find a reason of hope in that news. Like in his 
condition he’s got T2a N1 disease but there’s no M. And it’s only one lymph 
node, it’s only N1, not N2. So that’s a good thing because he could have been 
worse.” [Surgeon 6 interview about Patient 10] 
But other staff talked about providing a more realistic message. One surgeon 
spoke about the different approaches that colleagues sometimes take:  
“I mean it is very easy to give good news all the time. I don’t think it’s always 
appropriate. […] But that depends on whether you subscribe to like always 
say the good thing, patient feels hopeful, helps them in the treatment or 
whether you think you should be realistic and not create unrealistic 
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expectations. And I don’t, there’s no guidance in that. I think it is very much 
dependent on your own point of view and approach to it […].” [Surgeon 5 
interview about Patient 9] 
 
Many of the staff interviewed also stressed the need to provide an approach that 
was balanced and both helped to support hope as well as give a realistic view. 
Achieving the right balance between optimism and realism, hope and bleakness 
and detail or more general information was important for all the professionals. 
The balance point varied between cases and professionals, and appeared to be 
influenced not only by the clinical scenario and the patient, but also by individual 
clinicians’ communication beliefs and attitudes.   
 
Discussion 
These findings provide a unique insight into the views of professionals caring for 
lung cancer patients regarding information disclosure. They reveal the 
challenging nature and complexity of discussing recurrence following lung 
cancer surgery. Clinicians in this study varied in how they discussed issues 
related to recurrence. Styles of communication differed amongst patient 
professional pairs, and some differences were noted between the same 
professional when consulting with different patients.   
 
A spectrum of approaches was adopted in relation to risk communication and 
there were many similarities to the findings of Mendick et al. (2013). 
Professionals were largely cautious about presenting information about 
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recurrence beyond giving a possibility that it could happen. Good prognosis 
appeared to be conveyed to patients often without explicit discussion of 
recurrence, allowing patients to then ask for more information. This information 
was seen as hopeful and used to support patients’ positive views of surgery and 
the future. Even for these patients, many professionals regarded specific numeric 
probabilities of recurrence as damaging to hope and not useful to individual 
patients. This indicates the inherent uncertainty in such information and mirrors 
some of the findings of Thorne et al. (2006). Where prognosis was perceived to 
be less positive by clinicians, this was conveyed indirectly, such as discussing the 
referral to an oncologist. Recurrence was presented in terms of possibility only. 
Even when discussing adjuvant treatment patients did not ask about their 
underlying risk of recurrence or chance of survival and none of the oncologists in 
the study offered this. The benefits of adjuvant therapy were presented as 
absolute survival increase, or as comparative recurrence rates, with and without 
treatment. Zikmund-Fisher (2013) discussed these formats of risk 
communication as being suitable for treatment decision-making. However, 
where benefits of treatment were presented only in terms of comparative 
possibilities (as with Patient 8), it could be questioned whether this truly 
provides sufficient information for decision-making and informed consent.  
 
One explanation for this observed difference in whether patients ask further 
questions about their prognosis is that patients using gist level information, 
including tone and body language, rather than the verbatim account, in order to 
make an assessment of their outcome (Reyna, 2012). The manner that hope was 
conveyed to patients with a good prognosis, rather than explicit facts, may 
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determine whether patients felt safe to ask further questions, in the expectation 
of receiving further information likely to support hope. Other patients, although 
not explicitly told they had a poorer prognosis, may have taken the gist of the 
consultation and have realised that asking further information would not 
support hope.  
 
Information about signs and symptoms of recurrence and what to do about these 
were not consistently discussed with study patients following surgery, even 
when not having on-going treatment.  The National Cancer Survivorship 
Initiative advocates giving information on symptoms that might indicate 
recurrence or progression of disease at the end of primary treatment (NCSI, 
2014). The current study indicates that barriers may exist to implementing this 
with post-surgical lung cancer patients. This may in part be due to professionals’ 
desire to support patient hope (Thorne & Stajduhar, 2012). The lack of 
consensus on optimal follow-up programmes (National Collaborating Centre for 
Cancer, 2011) could also reduce clinician’s confidence in post-operative follow-
up, and so the whole approach to detecting early recurrence. There are limited 
options for treating patients with relapsed lung cancer and this may also 
influence attitudes to long-term surveillance and the value of increasing patient 
anxiety levels by discussing possible signs of recurrence. However, with recent 
developments in radiation and systemic therapy, as well as possible further 
resection, this situation may well begin to change (Goldstraw et al., 2011). 
  
Choices that staff make about information for post-surgical lung cancer patients 
are complex. These findings suggest that both clinicians and patients appeared to 
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be managing uncertainty as a dynamic process during these information 
exchanges. The findings are supported by previous literature and suggest a tacit 
agreement exists between professionals and patients with lung cancer to manage 
uncertainty in a way that promotes hope (Johnson et al., 2015).  Professionals 
talked about presenting information honestly and realistically, not damaging 
patients’ fragile hope by giving too much or the wrong type information. This 
was a priority for most clinicians, mirroring the findings of Mendick, et al. 
(2011). Some staff participants took either an optimistic or realistic approach to 
information giving. Most staff, however, emphasised the need to maintain a 
careful balance in their communication to meet the patient’s individual 
information needs. Judging this balance would appear to require a skilled clinical 
relationship that takes as its starting point the expertise of the clinician and the 
inevitable vulnerability of the patient (Salmon & Young, 2017). 
 
Study strengths and limitations 
This is the first in-depth exploration of the discussion of recurrence risk 
following lung cancer surgery. Examination of the multidisciplinary approach to 
these discussions, as patients move between teams, allows an understanding of 
how this disclosure process happens over time. Triangulation of the data 
between clinical observation of what was said, together with the professional’s 
rationale for the information that was given, allows a greater depth of 
understanding of the decision making processes involved in selecting the type 
and format of information.  As a qualitative case study, the sample was robust 
and was based on a good range of patients. The different cancer stages within 
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this study population exposed the difference in approach to information giving 
used by staff, when confronted with patients with divergent prognoses.  
 
However, patients were referred to a limited number of oncologists and staff 
undertaking long-term follow-up, resulting in some clinicians seeing multiple 
study patients. This may have limited the range of views and practices observed 
in the non-surgical element of the study in particular. In common with other 
qualitative studies, potential observer bias and the risk of post hoc justification 
among interviewees can clearly influence the results.  
 
Nevertheless, it is possible to draw out themes relevant to wider lung cancer 
practice. The idiosyncratic nature of clinical encounters is particularly 
highlighted, with clinicians drawing on their own personal values and style and 
working in the “art” of clinical practice, tailoring the approach to individual 
patients’ lives and health circumstances. Insight into the decisions around how 
long-term outcomes following surgery are presented provides a greater 
awareness of the underlying aims of communicating this information and 
recognition of the significance and complexity of the communication of 
prognostic information at this phase of treatment. This study highlights how 
nuanced and subtle some of this communication can be, with skills largely 
developed through experience. This understanding can be used to develop the 
skill sets and competencies of clinical staff to achieve the right balance in 
communicating about potential long-term outcomes that seeks to match 
patients’ coping strategies. Further research will include the patient views of 
these clinic consultations with the ultimate aim of highlight potential strategies 
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to support patients in survivorship and inform further research to develop 
potential interventions and communication strategies. 
Conclusion 
This study enhances the understanding of the challenges in communicating risk 
of recurrence following lung cancer surgery. It highlights how complex it is for 
clinicians to balance hope and uncertainty, whilst conveying the information that 
a patient may need.  Awareness of the strategies that clinical staff employ, often 
unconsciously, when talking with patients about difficult subjects, could help 
staff tailor their communication to individual patient information needs and 
coping style. It is important to recognise how significant and meaningful these 
consultations are for patients, and how subtle and complex the communication 
within them really is. Staff providing this care need to have the skills and support 
necessary to ensure this care is provide as well as possible.  
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Table 1: Details of patients and professionals included in the study  
 
Subject Age Diagnosis Stage Operation MDT Outcome Professionals involved and 
interviewed 
Patient 1 
(Female) 
75 Large Cell Neuroendocrine 
Carcinoma 
2A Pneumonectomy Refer to oncology Surgeon 1 
Oncologist 1 
Patient 2 
(Female) 
68 Squamous Cell Carcinoma 3A Bi-lobectomy Refer to oncology Surgeon 1 
Oncologist 1 
Patient 3 
(Female) 
58 Adenocarcinoma 1A Segmentectomy Follow up with LCNS Surgeon 2 
LCNS 2 
Patient 4 
(Female) 
56 Adenocarcinoma 1A Lobectomy Follow up with LCNS Surgeon 2, LCNS 1 
LCNS 2 
Patient 5 
(Male) 
73 Adenocarcinoma 1B Lobectomy Refer to oncology Surgeon 3, LCNS 3 
Oncologist 1 
Patient 6 
(Female) 
61 Adenocarcinoma Occult carcinoma Lobectomy Follow up with 
oncologist 
Surgeon 4, LCNS 4 
Oncologist 2 
Patient 7 
(Female) 
59 Adenocarcinoma 1A Lobectomy Follow up with LCNS Surgeon 5, LCNS 1 
LCNS 2 
Patient 8 
(Male) 
74 Squamous Cell Carcinoma 2A (R1) Sleeve lobectomy Refer to oncology Surgeon 3 
Oncologist 1 
Patient 9 
(Female) 
60 Adenocarcinoma 2B (R1) Lobectomy plus chest wall Refer to oncology Surgeon 5 
Oncologist 3 
Patient 10 
(Male) 
77 Adenocarcinoma 2A Lobectomy Follow up with chest 
physician 
Surgeon 6 
Chest Physician 1 
Patient 11 
(Male) 
73 Adenocarcinoma 1B (initally 
reported 1A) 
Lobectomy Follow up with chest 
physician 
Surgeon 8 
Chest Physician 2 
Patient 12 
(Female) 
69 Adenocarcinoma 2B Sleeve lobectomy Refer to oncology Surgeon 9, LCNS 6 
Oncologist 4, LCNS 7 
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Table 2: Taxonomy of risk concepts based on Zikmund-Fisher (2013) with 
examples from clinical transcripts in the study. 
Risk concept Illustrative example 
Possibility: 
The event might happen or might 
not happen 
Surgeon 1: because some of the glands inside the lung contained 
tumour, there is a theoretical risk of recurrence  
(Patient 1– surgical clinic) 
Implicit possibility: 
The event might happen or might 
not, but conveyed by means of a 
proxy, (eg discussing follow up) 
LCNS 2: so we are finished from the tumour point of view for the 
time being. Don't anticipate having to do anything different. 
And the plan would be to follow you up for the next few years  
(Patient 4 – follow up clinic) 
Categorical possibility: 
The event might or might not 
happen and the likelihood is 
conveyed as a category (eg high 
chance, low risk) 
Patient 3: And what's the possibility of it coming back? 
Surgeon 2: Well, what’s.. it's real really small, so the possibility is 
very low  
(Patient 3 – surgical clinic) 
Relative possibility: 
The event is more or less likely to 
happen due to a particular 
circumstance that exists 
Oncologist 3: And it is a little bit more likely to [come back] if 
the layers of the lung are involved  
(Patient 9 – oncology clinic) 
Comparative possibility: 
The event is more or less likely to 
happen in this circumstance as 
opposed to another circumstance 
Oncologist 1: The intended benefits are to reduce the risk of 
recurrence of the lung cancer. I am afraid it is not a hundred per 
cent guarantee, but it does reduce the risk  
(Patient 8 – oncology clinic) 
Absolute probability:  
The numerical estimate of the 
chance the event will happen 
Surgeon 8: The chances of it coming back is very small. Given the 
early stage of tumour it is only about ten to fifteen per cent.  
(Patient 11 – surgical clinic) 
Incremental probability: 
The numerical estimate of the 
change in the chance that an 
event will happen 
Oncologist 4: if I give a hundred people like you chemotherapy, 
five extra people would be cured of the cancer in addition to the 
surgery […] So there is a definite benefit to having the 
chemotherapy, but it is quite a small benefit  
(Patient 12 – oncology clinic) 
Comparative probability: 
The numerical estimate of the 
chance of the event will happen 
given one circumstance and the 
numerical estimate in an 
alternative circumstance  
Oncologist 3: I would estimate that the benefit from 
radiotherapy if I had a hundred of you in a room, would be, from 
a local control point of view, would be around about sixty per 
cent, maybe down towards fifty per cent without radiotherapy, 
and we would be going up into maybe the seventies and eighties 
with radiotherapy […] So it doesn't mean that it can't come back  
(Patient 9 – oncology clinic) 
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Table 3: Typology of Recurrence risk communication and recurrence risk in relation to adjuvant treatment in each clinic observation 
Patient 
(Gender, stage) 
Typology of recurrence information given Typology of recurrence information given 
Surgical clinic Follow-up clinic 
Patient 3  
(Female 1A)  
“G
o
o
d
 p
ro
gn
o
si
s”
 p
at
ie
n
ts
  Categorical possibility (patient question) 
Adjuvant treatment not indicated (surgeon initiated) 
Recurrence not discussed  
Adjuvant treatment not indicated (LCNS initiated) 
Patient 4  
(Female 1A) 
Categorical possibility (patient question) 
Adjuvant treatment not indicated (surgeon initiated) 
Implicit possibility  
Adjuvant treatment not indicated (LCNS initiated) 
Patient 6  
(Female occult ca) 
Categorical possibility (Patient question) 
Adjuvant treatment not required (husband initiated) 
Possibility (patient question) 
Adjuvant treatment not required (oncologist initiated) 
Patient 7   
(Female 1A) 
Absolute probability (Patient question) 
Adjuvant treatment not indicated (patient question) 
Categorical possibility (Patient question) 
Adjuvant treatment not indicated (patient initiated) 
Patient 11  
(Male 1A/B) 
Absolute probability (Surgeon initiated) 
Adjuvant treatment not indicated (surgeon initiated) 
Recurrence not discussed 
Adjuvant treatment not indicated (physician initiated) 
 Surgical clinic Oncology assessment clinic 
Patient 1  
(Female 2A) 
“I
n
te
rm
ed
ia
te
 p
ro
gn
o
si
s”
 p
at
ie
n
ts
 
Possibility (surgeon initiated) 
Possibility of adjuvant benefit (surgeon initiated) 
Possibility (oncologist initiated) 
Incremental probability of adjuvant benefit (oncologist initiated) 
Patient 2  
(Female 3A) 
Implicit possibility  
Comparative possibility of adjuvant benefit (surgeon initiated) 
Possibility (oncologist initiated) 
Incremental probability of adjuvant benefit (oncologist initiated) 
Patient 5  
(Male 1B) 
Implicit possibility 
Comparative possibility of adjuvant benefit (daughter’s question) 
Categorical possibility (patient question) 
Comparative possibility of adjuvant benefit (oncologist initiated) 
Patient 8  
(Male 2A, R1) 
Implicit possibility 
Implicit possibility 
Relative possibility (oncologist initiated) 
Comparative possibility (wife’s question) 
Patient 9  
(Female 2B, R1) 
Recurrence not discussed 
Implicit possibility of adjuvant benefit 
Relative possibility (oncologist initiated) 
Comparative probability of adjuvant benefit (patient question) 
Patient 10 
(Male 2A) 
Possibility (Patient question) 
Comparative possibility of adjuvant benefit (surgeon initiated) 
(NB Seen in follow-up clinic) Recurrence not discussed  
Adjuvant treatment not discussed 
Patient 12  
(Female 2B) 
Recurrence not discussed 
Adjuvant treatment not discussed 
Possibility (oncologist initiated) 
Incremental probability of adjuvant benefit (oncologist initiated) 
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Figure 1: Study recruitmernt and datacollection points 
(LCNS = Lung cancer nurse specialist) 
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Box 1: Inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
 Patient has had a surgical resection 
for primary lung cancer 
 Patient is aware they have or are 
likely to have lung cancer  
 Patient has not yet been seen in the 
first follow-up clinic  
 Patients referred from hospitals 
that are included in the study 
 Able to speak fluent English 
 
 Patients who do not meet the 
inclusion criteria 
 Patients under 18 years of age 
 Patients unable to give informed 
consent to participation in the study 
 Patients undergoing surgery where 
the aim is not curative (ie surgical 
biopsy, tumour de-bulking, “open 
and close” surgery). 
 Patients with a diagnosis of 
carcinoid tumour with no atypical 
features 
 Patients with a diagnosis of 
mesothelioma 
 Patients judged by the clinical team 
to be emotionally or psychologically 
unstable 
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Box 2: Interview topic guide for interviews with professionals following consultations 
 
 
Interview topic guide  
1. Introduction to the interviews. 
2. Explore staff member’s perception of this patient’s risk of recurrence 
3. Explore their perception of the role of adjuvant therapy in this case 
4. Understand how the decision was made as to what information to present to 
the patient in relation to histopathology and surgical findings 
5. Use key points in the clinic encounter to ask why they chose to use a particular 
phrase or to give/not give particular information 
6. Explore what the staff member is trying to achieve when giving information to 
patients regarding diagnosis and prognosis 
7. What do they see as the benefits of information giving regarding detailed 
clinical information and risk of recurrence? 
8. What do they see as the risks or problems with giving detailed clinical 
information and risk of recurrence? 
9. Explore who they feel has responsibility, or is best placed, within the patient’s 
MDTs to discuss diagnosis and prognosis or risk of recurrence with patients 
10. Explore the staff member’s concept of the way that this patient manages the 
emotional challenge of living with the risk of lung cancer recurrence. 
11. What does the staff member see as their role in helping patients face this 
challenge? 
12. Explore what the terms “hope” and “uncertainty” mean to the staff member in 
the context of cancer  
13. Explore the implications of these concepts for lung cancer patient management  
14. Interview close 
 
 
